NCT02122003终止2 期
Activity and Safety of Second Line SOrafenib After Pazopanib in Patients With Metastatic Renal Cell Carcinoma (SOAP Study)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2016年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Progression Free Survival (months) of patients treated with sorafenib after progression to pazopanib
研究概览
简要总结
- Retrospective studies showed Sorafenib's efficacy as second line treatment after a Tyrosine Kinase Inhibitor (TKI).
- Currently there is no standard of treatment in 2nd line for patients treated in first line with pazopanib for metastatic Renal Cell Carcinoma (mRCC).
- With this trial we evaluate the efficacy of sorafenib as second line of treatment in patients treated with pazopanib for mRCC.
详细描述
- Retrospective studies showed Sorafenib's efficacy as second line treatment after a TKI: AXIS study showed sorafenib activity, in terms of Overall Response Rate (ORR), and the absence statistically significant difference in Overall Survival (OS) between the 2 arms, although there is a significant OS increase of 1.4 months in the Axitinib arm. The INTORSECT study (temsirolimus vs sorafenib in 2nd line after sunitinib) didn't demonstrate statistically significant difference for Progression Free Survival (PFS), but it showed an OS increase in patients treated with sorafenib.
- The COMPARZ study demonstrated the non-inferiority of pazopanib vs sunitinib in 1st line of treatment for mRCC.
- Currently there is no standard of treatment in 2nd line for patients treated in first line with pazopanib for mRCC.
- Primary objective:to evaluate the efficacy of sorafenib (PFS) as second line of treatment in patients treated with pazopanib for mRCC.
- Secondary objectives: To evaluate the safety of sorafenib in patients previously treated with pazopanib. To evaluate the Overall Survival. To evaluate the Quality of Life through specific questionnaires (FKSI-19; European Organization for Research and Treatment of Cancer quality of life questionnaire -C30).To assess the predictive role for PFS and OS of arterial blood pressure increase from baseline to week 4 and 8 after start of treatment with sorafenib. To assess the predictive role for PFS and OS of hand-foot syndrome before week 4 and 8 after start of treatment with sorafenib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Patients with histological diagnosis of Renal Cell Carcinoma (RCC)
- •Measurable disease
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •Life expectancy of at least 12 weeks.
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- •Hemoglobin >= 10.0 g/dl
- •Absolute neutrophil count (ANC) >1,500/mm3
- •Platelet count >= 100,000/ml
- •Total bilirubin ≤ 1.5 times the upper limit of normal
- •ALT and AST ≤ 2.5 x upper limit of normal
- •Alkaline phosphatase ≤ 4 x upper limit of normal
- •prothrombin time-international normalized ratio /partial thromboplastin time ≤ 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists.] For patients on warfarin, close monitoring of at least weekly evaluations will be performed, until international normalized ratio is stable based on a measurement at pre-dose, as defined by the local standard of care.
- •Prognosis according to Heng: good or intermediate
- •Previous treatment with pazopanib
- •Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and two weeks after the completion of trial.
- •Signed informed consent must be obtained prior to any study specific procedures
排除标准
- •First line treatment for metastatic RCC other than pazopanib.
- •History of cardiac disease: congestive heart failure >New York Heart Association class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension (>= 160 mmHg systolic and/or 90 mmHg diastolic).
- •History of HIV infection
- •Active clinically serious infections (> grade 2 NCI-CTC version 3.0)
- •Brain or meningeal metastases
- •Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
- •History of organ allograft
- •Patients with evidence or history of bleeding diathesis
- •Patients undergoing renal dialysis
研究组 & 干预措施
sorafenib
Experimental
Sorafenib 400 mg bid
干预措施: Sorafenib (Drug)
结局指标
主要结局
Progression Free Survival (months) of patients treated with sorafenib after progression to pazopanib
时间窗: 24 months
次要结局
- Safety profile of sorafenib using Common Terminology Criteria for Adverse Events (CTCAE) criteria v.4.0 in patients previously treated with pazopanib(24 months)
- Overall Survival (months) of patients treated with sorafenib after pazopanib progression(24 months)
- Quality of Life of patients treated with sorafenib after pazopanib progression using the specific questionnaires FKSI-19 and European Organization for Research and Treatment of Cancer quality of life questionnaire -C30.(24 months)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric CancerGastric CancerNCT00595985Fudan University5
进行中（未招募）
不适用
A Phase II Trial of Sorafenib (a tyrosine kinase inhibitor) given orally twice daily in renal cancer patients with vHL syndrome - Oral Sorafenib in renal cancer patients with vHL syndromevon Hippel Lindau syndrome (vHL) is a rare genetic disorder that causes a predisposition to develop multiple tumours, including renal, CNS and retinal tumours. vHL patients who have solid renal tumours (< or =2.4 cm) will require surgery to remove the renal tumours once they reach 2.5cm or greater. Disease-stabilising agents such as sorafenib could potentially delay or avoid the need for surgery.MedDRA version: 9.1Level: LLTClassification code 10047716Term: Von Hippel-Lindau diseaseEUCTR2007-002132-29-GBOxford Radcliffe Hospitals NHS Trust25
已完成
2 期
Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT StudyAdvanced Hepatocellular CarcinomaNCT05117957Bo Hyun Kim50
进行中（未招募）
1 期
Study to evalueta the activity and safety of sorafenib when used as second line of therapy after pazopanib in patients affected by metastatic renal cell carcinoma.MedDRA version: 16.1Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-000777-38-ITFondazione IRCCS Istituto Nazionale dei Tumori44
终止
2 期
Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast CancerBreast CancerNCT00525161Suleiman Massarweh11